Mountain Crest Acquisition Corp. II (MCAD) to Combine with Better Therapeutics in $187M Deal

Mountain Crest II (NASDAQ:MCAD) has entered into a definitive agreement to combine with biopharmaceutical firm Better Therapeutics at an enterprise value of $187 million. Better Therapeutics provides prescription digital therapeutics (PDT) that deliver behavior-based therapy to address the root causes of cardiometabolic diseases. The combined company is expected to be listed on the Nasdaq under
Read More